TORONTO, ON / ACCESSWIRE / March 29, 2017 / Deveron UAS Corp. (CSE: DVR) (“Deveron” or the “Company”), is pleased to announce that it has retained First Republic Capital Corporation (the “Agent”) to act as lead agent in connection with a best efforts brokered private placement to raise gross proceeds of up to $1,050,000 through the issuance of up to 3,000,000 units of the Company (the “Units”) at a price of $0.35 per Unit (the “Offering”). Each Unit consists of one common share in the capital of the Company (a “Common Share”) and one half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will entitle the holder to purchase one Common Share of the Company (a “Warrant Share”) at a price of C$0.50 per Warrant Share for a period of 18 months after the closing of this Offering. In addition, the Company has granted the Agent an over-allotment option to sell up to an additional 5,000,000 Units for aggregate proceeds of $1,750,000, exercisable at any time up to date of the closing of the Offering.

In connection with the Offering, the Agent will be entitled to a corporate finance fee in an amount equal to 2% of the aggregate gross proceeds of the Units sold and a sales commission equal to 7% of the aggregate gross proceeds of the Units sold. In addition, as additional compensation, the Company will issue to the Agent corporate finance warrants entitling the Agent to purchase a number of Common Shares equal to 2% of the aggregate number of Units sold and selling compensation warrants entitling the Agent to purchase a number of Common Shares equal to 7% of the aggregate number of Units sold, at an exercise price of $0.35 per compensation warrant for 18 months from the date of closing. The Company expects closing to be on or before April 12, 2017.

Net proceeds of the Offering will be used by the Company to further the business of the Company and for general working capital purposes.

About Deveron UAS:

Deveron is an enterprise drone data services company focused on agriculture, offering the opportunity to increase yields and reduce costs using sophisticated Unmanned Aerial Systems (“UAS” or “drones”), sensors, software and analytics. Deveron’s drone data service network allows enterprise level customers to obtain on-demand, actionable data without exposure to technology and capital risks. The Company is focused on building a standardized constellation of drones and sensors to provide data in North America.

For more information and to join our community, please visit www.deveronuas.com or contact:

David MacMillan
President & CEO
Deveron UAS Corp.
416-367-4571 ext. 226
dmacmillan@deveronuas.com

This news release includes certain “forward-looking statements” within the meaning of that phrase under Canadian securities laws. Without limitation, statements regarding future plans and objectives of the Company are forward looking statements that involve various degrees of risk. Forward-looking statements reflect management’s current views with respect to possible future events and conditions and, by their nature, are based on management’s beliefs and assumptions and subject to known and unknown risks and uncertainties, both general and specific to the Company. Although the Company believes the expectations expressed in such forward-looking statements are reasonable, such statements are not guarantees of future performance and actual results or developments may differ materially from those in our forward-looking statements. The following are important factors that could cause the Company’s actual results to differ materially from those expressed or implied by such forward looking statements: changes in the world wide price of agricultural commodities, general market conditions, risks inherent in agriculture, the uncertainty of future profitability and the uncertainty of access to additional capital. Additional information regarding the material factors and assumptions that were applied in making these forward looking statements as well as the various risks and uncertainties we face are described in greater detail in the “Risk Factors” section of our annual and interim Management’s Discussion and Analysis of our financial results and other continuous disclosure documents and financial statements we file with the Canadian securities regulatory authorities which are available at www.sedar.com. The Company undertakes no obligation to update this forward-looking information except as required by applicable law. The Company relies on litigation protection for forward looking statements.

SOURCE: Deveron UAS Corp.

ReleaseID: 458463

CreditEase Fintech Investment Fund leads, Wonderful Sky Financial Group, OSK Ventures International, Among Others, Join as New Investors

HONG KONG and NEW YORK / ACCESSWIRE / March 29, 2017 / WeConvene today announced that new and existing investors have joined the company’s $12.5 million series B funding round. The venture firm and round leader was the CreditEase Fintech Investment Fund, along with other investors: Wonderful Sky Financial Group (1260 HK) and OSK Ventures International Berhad (OSKV MK), which are also taking part in WeConvene’s first institutional round.

Credit Ease’s Nina Zhou, who will join WeConvene’s Board of Directors, commented that, “WeConvene’s focus on innovation for the capital markets stood out to us because it was powered by a technology advantage and competitive strategic partnerships, key criteria for our investments. Global capital market players are looking for digital-first ways to better manage the corporate access process, and WeConvene has developed an agile and intuitive platform for buy-side, sell-side and corporates and has true potential to address a variety of other business needs, all within one elegant solution.”

The CreditEase Fintech Investment Fund “aims to support category leaders within the global Fintech space. WeConvene’s platform for the global capital markets community is remarkable and has the potential to provide higher agility, transparency and efficiency that the buy-side, sell-side and corporates need as they make a push toward greater digitization,” said CreditEase Founder and CEO, Ning Tang. “We are excited to support their global ambitions and expansion plans.”

Patrick Yee, Executive Director of OSK Ventures International, added, “WeConvene’s ability to forge strategic partnerships and access to global stakeholders sets it apart from its peers. We believe WeConvene will continue to ride on the wave of further financial digitization as investors continue to seek better access to corporates globally.”

WeConvene‘s CEO and founder, Radek Barnert, added, “We are excited to welcome our new investors to the company. With their shared vision and support, WeConvene will be able to accelerate its growth and delivery of exciting solutions to our clients.”

WeConvene will use the funding to expand its sales and development teams globally to meet client demand for an independent MiFiD II compliant technology platform that brings a broad range of efficiencies to corporate access workflows.

About WeConvene:

WeConvene is a global web-based platform designed to eliminate the inefficiencies of managing the corporate access process for the investment community. Events large and small can impact investment strategies and WeConvene provides value to both buy and sell side customers by enabling efficient discovery, booking and tracking of meetings. For more information, visit www.weconvene.com.

Contact:

Sarah Linfoot

sarah@weconvene.com

SOURCE: WeConvene

ReleaseID: 458266

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Depomed continued the shakeup of its Board of Directors, while Insys reorganizes its own board. Both companies were down slightly, after there was an announcement of a Federal investigation into their opioid market sale and regulations. The opioid problem has recently become the focus of attention for media and government officials.

RDI Initiates
Coverage:

Depomed Inc. https://ub.rdinvesting.com/news/?ticker=DEPO

Insys Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=INSY

Depomed stumbled 4.50% to close at $14.23 on Tuesday. The stock traded between $14.84 and $14.13 on volume of 1,777,969 shares traded. The news for the company over the past few days has been anything but completely positive, as Senator Claire McCaskill, a Democrat from Missouri, has begun an investigation into the opioid prescription market. Depomed was one of five companies selected for the investigation, whose stated goal is to examine, “the challenges industry practices pose to efforts to curb opioid addiction.” After trading hours, it was announced that the company has replaced its Chief Executive and appointed two new Directors to its board. The new Director, CEO, and President will be Arthur Higgins, and the two other board members will be William McKee and Gavin Molinelli. James Fogarty will serve as the Chairman.

The replacements are all from Starboard, LP, which has nearly 10% stake in Depomed, and has been seeking the removal of the original Depomed Board of Directors ever since Depomed fought off a takeover bid at $33 a share from Horizon Pharmaceutical in 2015. With that objective accomplished, the question for investors is whether Depomed will once again become a takeover target.

Access RDI’s Depomed Research Report at: https://ub.rdinvesting.com/news/?ticker=DEPO

Insys Therapeutics fell 0.72% to close at $11.00 on Tuesday. The stock traded between $11.38 and $10.76 on volume of 683,792 shares traded. Like Depomed, Insys was another of the selected companies to be investigated by the Federal government. Monday, the company announced that effective April 17th of this year, Saeed Motahari will become the company’s new President and Chief Executive Officer, and a member of the Board of Directors.

Chairman of the Board of Directors, Steven Meyer, gave high praise to Motahari, saying “We believe Saeed can execute on the promise of this business including the anticipated commercial launch of Syndros(TM) and the potential products in our pipeline.”

Access RDI’s Insys Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=INSY

Our Actionable Research on Depomed Inc. (NASDAQ: DEPO) and Insys Therapeutics Inc. (NASDAQ: INSY) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458439

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Freeport-McMoRan Inc. has been receiving criticism about the value of its stock price. The shares are now deemed too expensive and not worth buying by the industry’s most prominent analysts. It comes as no surprise, given the company’s low turnover over the past 12 years. Cliffs Natural Resources is re-engineering its financial administrative organ. Let’s see how the two miners are performing at the stock exchange market.

RDI Initiates
Coverage:

Freeport-McMoRan Inc. https://ub.rdinvesting.com/news/?ticker=FCX

Cliffs Natural
Resources Inc. https://ub.rdinvesting.com/news/?ticker=CLF

The mining firm’s stock price is currently fluctuating in between $12.1 and $12.7, having reached a low of $12.15 earlier yesterday morning. Currently at $12.59, the mining firm’s volume of trade yesterday crossed 22.9 million.

Experts still insist the current stock is yet to be convincingly worth buying. Analysts cite slow turnover, with the company having delivered a cumulative 4% return since 1995. With an average 2.6% return on dividend, the current share price is on the higher end, according to industry analysts. The stock price has fell by an average 25% from the recent highest trade level. Experts also have it that the slow upward trend is unlikely to change, deeming the stock price too expensive and non-worthy.

Access RDI’s Freeport-McMoRan Research Report at: https://ub.rdinvesting.com/news/?ticker=FCX

Cliffs’ stocks have been almost stagnant, holding water at the $8.27 mark, with the dip and surge rate being 2.9% and 1.6% respectively. The share price however hit lows of $8.03 earlier yesterday morning, with the trading volume currently standing a bit over the 14 million mark.

Overall, the company’s annual performance has been astronomical, but recent data reveals a 26% dip in the share price from the all-time high of $12.37 to the current $8.27. As of February 2017, there were plans underway to issue 500 million senior notes due 2025. The notes are secured by Cliff’s domestic subsidiaries. Proceeds from the issuance of notes will most likely be used for redeeming two senior secured notes due 2020. The financial re-engineering is expected to bring savings of 50 million in interest expense to the company. The company is currently cleaning up its balance sheet, but analysts warn of an imminent shareholder dilution.

Access RDI’s Cliffs Natural Resources Research Report at:
https://ub.rdinvesting.com/news/?ticker=CLF

Our Actionable Research on Freeport-McMoRan Inc. (NYSE: FCX) and Cliffs Natural Resources Inc. (NYSE: CLF) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458442

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Two stocks that are looking to secure their futures after less than inspiring 4th quarter financials, Seadrill and Transocean both need to weather the current storm of low oil prices. Seadrill may be rescued by another oil and gas exploration company, while Transocean plans to move to riskier, yet potentially more lucrative, drilling fields to achieve stable financials.

RDI Initiates
Coverage:

Seadrill Ltd. https://ub.rdinvesting.com/news/?ticker=SDRL

Transocean Ltd. https://ub.rdinvesting.com/news/?ticker=RIG

Seadrill advanced 7.80% to close at $1.52 on Tuesday. The stock traded between $1.59 and $1.40 on volume of 19.07 million shares traded. Seadrill is a Bermuda owned company that has reported positive financial news recently. On February 28th, the company reported 4th quarter financial data, with revenues of $667 million and an operating income of $118 million. With nearly $3.4 billion of debt due starting from April 30th, and the delay in restructuring, ignited the possibility of both bankruptcy filings and also a rumor of another investor stepping up to assist the company with their debt. On Tuesday, a Bloomberg media outlet reported that the company’s debt may be taken over by Billionaire John Fredriksen, saving the company from its financial distress.

Access RDI’s Seadrill Research Report at: https://ub.rdinvesting.com/news/?ticker=SDRL

Transocean advanced 1.49% to close at $12.23 on Tuesday. The stock traded between $12.33 and $11.99 on volume of 10.75 million shares traded. The company is an international provider of offshore contract drilling services for oil and gas wells. The company’s current drilling areas are packed with very intense competition and as of February 9, 2017, the company’s contract backlog was $11.3 billion. Investor circles are looking for possibility for Transocean to explore using its existing cash reserves to explore further offshore, in ocean areas where the environmental conditions are harsher, but there is less competition for resources. The stock has fallen 14.3% since 23rd February as its 4th quarter earnings report was announced. Transocean’s last financial report included a quarterly revenue reduction of $974 million, which was down 47% compared to one year ago.

Access RDI’s Transocean Research Report at: https://ub.rdinvesting.com/news/?ticker=RIG

Our Actionable Research on Seadrill Ltd. (NYSE: SDRL) and Transocean Ltd. (NYSE: RIG) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458438

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / These two companies, one involved in cancer drug research, the other in cholesterol testing devices, both saw their stocks rise as investors heard of their noted industry achievements. The distribution channel of Akers is worth noting, and the early success of Diffusion may not be as promising as it is perceived.

RDI Initiates
Coverage:

Diffusion
Pharmaceuticals Inc. https://ub.rdinvesting.com/news/?ticker=DFFN

Akers Biosciences
Inc. https://ub.rdinvesting.com/news/?ticker=AKER

Diffusion Pharmaceuticals advanced 81.75% to close at $4.98 on Tuesday. The stock traded between a wide range of $5.06 and a low of $2.619 on volume of 7.59 million shares traded. The company develops therapies for cancer and other hypoxia-related diseases. Stock prices yesterday leaped $2.24 a share, actually without any kind of official news release from the company. Diffusion has however said in its release on February 8th, that the company’s TSC Phase I/II Glioblastoma Multiforme clinical trial results have been published in the February 2017 Edition of The Journal of Neurosurgery.

Diffusion Pharmaceutical’s lead clinical trial drug, TSC, was tested in 59 patients. Results showed 36.3% of the patients who received a full dose of the TSC candidate were alive two years later, moderately positive compared to the historical two year survival rates that range from 27% to 30%. David Kalergis, Chairman and CEO, said,”The very encouraging data from our Phase I/II clinical trial supports our strategy to advance into Phase III clinical development.”

Access RDI’s Diffusion Pharmaceuticals Research Report
at: https://ub.rdinvesting.com/news/?ticker=DFFN

Akers Biosciences exploded 67.86% to close at $2.35 on Tuesday. The stock traded between $2.90 and $1.80 on volume of 7.34 million shares traded. The company has received its first order for its primary FDA approved product, rapid cholesterol self-test from First Check diagnostics. Akers Bio’s Tri-Cholesterol “Check” test is the only combined rapid cholesterol test that provides an accurate estimate of a person’s total cholesterol and their High Density Lipoprotein (“HDL”) cholesterol levels. The potential for the product is tremendous, as it is disposable, requires only a finger-stick blood sample (much like diabetic blood testing kits), and gives a result in 5 minutes. The significance of this first order is that First Check products are sold at a number of major retailers: CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop and Shop, Giant and ShopKo, among others.

Access RDI’s Akers Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=AKER

Our Actionable Research on Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) and Akers Biosciences Inc. (NASDAQ: AKER) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458440

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Amazon and Tesla have made significant moves to expand their product lines nationally and internationally, moving their shares upward today. As American companies continue to encounter global competition for their products, these companies are responding by increasing their global presence.

RDI Initiates
Coverage:

Amazon.com, Inc. https://ub.rdinvesting.com/news/?ticker=AMZN

Tesla Inc. https://ub.rdinvesting.com/news/?ticker=TSLA

Amazon.com streaked 1.08% to close at $856.00 on Tuesday. The stock traded between $858.46 and $850.10 on volume of 3.04 million shares traded. Yesterday, Amazon expanded its e-commerce presence by buying Middle Eastern E-Commerce site Souq.com. By purchasing Souq.com, which has nearly 45 million visits per month with presence in Gulf Countries and Egypt, for reportedly more than $1 billion can be considered acceptable risk for Amazon as it now has a firm foothold in a Middle Eastern online shopping market that is relatively small, but has considerable growth potential.

Amazon also opened its drive-in-grocery delivery stores today in Seattle, Washington. The two stores, called AmazonFresh Pickup, are a part of a trial program currently only available to employees, but will expand to all Amazon Prime members in the future. The company also announced its plans to open a new fulfillment center in Clear Brook, Virginia. More than 1,000 full-time associate roles will be available. The online giant, which has started its business by selling books, has successfully expanded its business by implementing innovative business ideas and unique products to their customers, is now focusing on grocery business and it is attempting to launch AI based cashier free convenience store. Perhaps, the strength in the Amazon’s stock price lies in its ability to come up with new and successful business ideas while exploring new markets.

Access RDI’s Amazon Research Report at: https://ub.rdinvesting.com/news/?ticker=AMZN

Tesla advanced 2.68% to close at $277.45 on Tuesday. The stock traded between $280.68 and $275.00 on volume of 7.99 million shares traded. Tesla’s stock rise yesterday can be summed up in a single word – Tencent is the most valuable company in China, and its announced $1.8 billion investment in Tesla bodes well for Tesla’s future growth. The Tencent investment amounts to a 5% stake in Tesla. The company, which produces electric cars, has moved forward into mass production of its electric cars, developing and producing the Model 3, with a price tag of the $35,000.

Tesla has now almost same market cap as that of Ford but Tesla’s sales is a fractional in comparison to the Ford’s sales. Some investors are not getting overly excited about the deal as there are higher priced models Tesla produces that are not selling, including the Model S and Model X. As Elon Musk recently tweeted video showing model 3 prototype and saying it is almost ready, there are chances of delay in production and final delivery of the Model 3. American automaker General Motors is increasing pressure on the Model 3 as it has its own electric car, the Chevy Bolt, as an alternative for environmentally concerned consumers.

Access RDI’s Tesla Research Report at: https://ub.rdinvesting.com/news/?ticker=TSLA

Our Actionable Research on Amazon.com, Inc. (NASDAQ: AMZN) and Tesla Inc. (NASDAQ: TSLA) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458437

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / AK Steel is currently engaged in a publicity crisis, with the company facing sanctions from the Occupational Health and Safety Administration. OSHA expects a report on the findings of the ongoing investigations. United States Steel Corporation is expecting to turn its stock price fortunes, amid the tax reforms looming large. Here’s a closer look at the numbers.

RDI Initiates Coverage:

AK Steel Holding
Corporation https://ub.rdinvesting.com/news/?ticker=AKS

United States Steel
Corporation https://ub.rdinvesting.com/news/?ticker=X

AK Steel started trading at $7.11, and by midday, with the steel manufacturer’s stock price on an inconsistent bullish upward surge. The problem however is not with the stock market but on the company’s internal employee woes.

The company is currently facing sanctions form OSHA, the occupational health and safety watchdog. On March 22, OSH sent a letter to the company’s Middletown plant to investigate cases of workplace hazards involving the welding unit of the plant. OSHA makes random inspections on factories and plants, to ensure all working conditions are met. Lisa Jester, AK Steel Spokesperson, however, said they are working with OSH in a “non-formal capacity” while approaching the situation. The company has until today, Wednesday, March 29, 2017 to submit a report of the investigations.

Access RDI’s AK Steel Research Report at: https://ub.rdinvesting.com/news/?ticker=AKS

United States Steel shares plummeted 0.03% early morning yesterday, with the company currently trading at $33.17, and had earlier fell even lower to $31.85. Investors are on high alert, amid the fluctuating legislative uncertainties from White House.

The anticipation of corporate Tax Reforms under the new presidency is slowly gaining traction, as companies are now rubbing their hands together for an expected tax relief. X Corporation is at the center of the anticipated reform, with its stock price being influenced by deregulation and infrastructure spending. S&P futures fell below the 50-day average for the first time since President Trump took office. Traditional analysis techniques would suggest that this is not a positive. However, with the emergence of “smart investments”, traditional analysis may not be able to give an accurate projection of what will happen in the future.

Access RDI’s United States Steel Research Report at: https://ub.rdinvesting.com/news/?ticker=X

Our Actionable Research on AK Steel Holding Corporation (NYSE: AKS) and United States Steel Corporation (NYSE: X) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458443

GOLDEN, CO / ACCESSWIRE / March 29, 2017 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma, announced the completion of a bridge loan in the amount of $125,000 and the execution of a Memorandum of Understanding (“MOU”) outlining the terms of a larger, subsequent financing to provide a total of not less than $1.7 million. Completion of the subsequent larger financing through the execution of a definitive agreement would initiate the establishment of a stem cell center of excellence in the Grand Cayman Islands. The bridge loan is provided by the Caribbean GC Development Fund, Ltd; a Cayman-based company specifically organized to fund stem cell projects in Grand Cayman.

“The benefits of the award-winning stem cell technology that Vitro Biopharma brings combined with the pristine and affluent environment of Grand Cayman and the availability of highly trained professional staff makes for a prolific, highly professional and cutting edge organization that directly addresses the immediate needs for those who are requiring the very best care available,” commented, Mr. William W. Becker, CEO of the Caribbean GC Development Fund, Ltd. Vitro Biopharma has recently established Halo Cell Sciences, Ltd.(“HCS”) as a wholly owned subsidiary incorporated under the laws of the Grand Cayman Islands. HCS will provide the platform and benefit to Vitro Biopharma in expanding its focus to include the application of its technology, products & services for various unmet medical needs in regenerative medicine. Stem cell therapy is evolving through early stage clinical trials as a therapeutic option for treatment of skeletal-muscular conditions such as osteoarthritis, various neurological conditions and cardiovascular disease.

Dr. Jim Musick, Ph.D., President and CEO of Vitro Biopharma said, “We continue to see growth of our product and service revenue as we move towards the achievement of profitability. We plan to use our increased resources to gain SEC compliance, expand operations and to access new distribution channels & capital. Our team has recently been expanded to include the expert services of John R. Evans as CFO. John has extensive financial experience as CFO/CEO of start-ups & large capital firms with $250 million in revenues. John’s expertise also includes raising significant capital, numerous M&A transactions, several successful IP licenses and strategic business development. I value his services and look forward to enhanced operational efficiency and expanded growth due to his addition to our team. Together with our advanced, propriety stem cell technology, products and services, we are well-positioned to capitalize on the growing global market for stem cell-based regenerative medicine. As is the case with our existing Fortune 100 clients, the Caribbean GC Development Fund chose us because of our highest of quality standards and technological advancements. Our expanding array of technology and services affords stem cell-based regenerative medicine approaches providing new avenues of treatment to several conditions that have previously been treated only at a symptomatic level.”

John R Evans said, “I am pleased to be on the team with Jim who is taking his leading edge research from the lab into practical applications that are going to drive the corporate revenue growth for years ahead.”

About Vitro Biopharma

Vitro Biopharma’s (http://www.vitrobiopharma.com/) mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern, GMP-compliant biotechnology manufacturing and R&D facility in Golden, Colorado. Vitro Biopharma manufactures and sells “Tools for Stem
Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation. Our cell lines also include cancer-associated fibroblasts (CAFs) derived from lung, colorectal, ovarian, uterine, breast and pancreatic tumors. In addition, we provide MSC-derived progenitor cells, including neural stem cells (NSCs), nephron progenitor cells (NPCs) as well as a growing line of terminally differentiated cells: cholinergic, dopaminergic and sensory neurons, osteoblasts, chondrocytes, cardiomyocytes, and renal tubular epithelial cells. A primary application of these terminally differentiated cells is cell-based assays for drug discovery and pre-clinical toxicology of drugs, drug candidates and drug combinations that may produce toxic effects on cardiac, neural or renal cells, either directly or through metabolites derived from the interaction of drugs with specific cells such as liver cells. Vitro Biopharma now provides its Clinical Grade MSC-Gro™ Media for expansion of stem cells prior to transplantation for clinical studies of osteoarthritis treatment and products for use in preliminary studies of stem cell activation therapy for ASD & autoimmunity.

Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.

Mission Statement: “As a leader in stem cell technology we manufacture and distribute multiple stem cell therapies for the treatment of degenerative diseases.”

About the Caribbean GC Development Fund Ltd.

Is a special purpose corporation based in the Grand Cayman Islands with a specific goal of addressing the demand for stem cell therapies and the continued research in the field of regenerative medicine for both local markets and the multi-billion dollar medical tourism industry.

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com

SOURCE: Vitro Diagnostics, Inc.

ReleaseID: 458395

NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Stocks of both companies rose on future-oriented news for investors. While FDA clinical trials continue, both companies are getting positive news coverage from their latest actions.

RDI Initiates
Coverage:

Osiris Therapeutics,
Inc. https://ub.rdinvesting.com/news/?ticker=OSIR

Omeros Corporation https://ub.rdinvesting.com/news/?ticker=OMER

Osiris Therapeutics advanced 19.75% to close at $4.73 on Tuesday. The stock traded between $4.9385 and $4.10 on volume of 305,977 shares traded. The Company was delisted from NASDAQ on March 14th, due to failure to keep the stock exchange up to date with its current financial statements, as the company has previously informed the exchange about material inaccuracies in its books of accounts. Yesterday, the company announced that it has completed the required financials by filing an amended Form 10-K/A for 2014 with the SEC where it has restated product revenue for the year 2014 to $50.8 million, slightly higher than estimated range of restated revenue of $46 million to $50 million, however restated loss for the year 2014 also increased significantly to $10 million or $0.29 a share, higher than previously reported net loss of $1.8 million or $0.05 a share. The new data shows slight Additionally, Osiris anticipates increases in product revenue for 2015 and 2016: Revenue in the range of $89 million to $92 million, up from previously announced range of $85 million to $90 million for year 2015 and revenue in the range of $110 million to $114 million, up from previously announced range of $100 million to $110 million for year 2016. Osiris develops and markets its products in the areas of wound care, orthopedics, and sports medicine. Investors expect the company will begin the process of refiling an application to be reinstated to the NASDAQ.

Access RDI’s Osiris Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=OSIR

Omeros investors saw their company’s stock rise 11.29% to close at $14.10 on Tuesday. The stock traded with significant price swings, ranging from a high of $16.40 to a low of $12.51 on volume of 3.67 million shares traded. The company develops and commercializes therapies targeting inflammation, coagulopathies, and disorders of the central nervous system. On March 1st of this year, Omeros announced positive data results from its ongoing Phase II clinical trial evaluating its lead candidate OMS721 drug. The positive results have brought offers for the company to present its results from the Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome on April 22nd to the World Congress of Nephrology. Additionally, the company has been invited to present the test results at the annual meeting of the European Society for Blood and Marrow. Transplantation. Omeros has witnessed significant revenue growth in the fourth quarter and full year of 2016 and has reported loss of $19.6 million or $0.45 a share and $66.75 million or $1.65 a share, for the fourth quarter and full year of 2016 respectively. Company had $45.3 million in cash assets as on December 31st, 2016.

Access RDI’s Omeros Corporation Research Report at: https://ub.rdinvesting.com/news/?ticker=OMER

Our Actionable Research on Osiris Therapeutics, Inc. (OTC PINK: OSIR) and Omeros Corporation (NASDAQ: OMER) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458450